小児歯性感染症に対する Cefditoren pivoxil の臨床的検討

抄録

The clinical efficacy and safety of Cefditoren pivoxil as a treatment for pediatric oral infections such as periodontitis and osteitis were evaluated in 18 institutions.
The results were as follows:
1) Clinical efficacy
The overall clinical efficacy rate determined according to the standards established by the Committee was 98.4%. By disease, the efficacy rates were 96.9% and 100% for periodontitis and osteitis, respectively.
2) Bacteriological response
The eradication rate against infecting organisms from 47 patients was 93.6%, and the disappearance rate of 115 strains isolated as infecting organisms was 98.3%.
The MIC₅₀ and MIC₉₀ values of Cefditoren pivoxil against 115 clinically isolated strains were 0.10 and 3.13μg/mL, respectively. For 60 aerbes strains, the MIC₅₀ and MIC₉₀ values were 0.10 and 0.78μg/mL. Against 56 strains of oral streptococci, the range of MIC was ≤ 0.025 to 3.13μg/mL.
The MIC₅₀ and MIC₉₀ values against 55 strains of anaerobes were 0.10 and 50μg/mL, respectively.
3) Safety
Mild side effects (watery stool) occurred in 1 (1.4%) of the 72 patients treated and slightly abnormal laboratory findings (Eos.↑) were found in 4 (6.9%) of 58 patients examined.